AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 51 min read$PLUS

Marion Elaine D sold $690K of PLUS (indirect holdings)

Marion Elaine D (CHIEF FINANCIAL OFFICER) sold 7,182 indirectly-held shares of EPLUS INC (PLUS) at an average of $96.11 ($95.12–$97.40, $0.69M total) across 4 trades over 2026-08-03 to 2026-08-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Marion Elaine D
Published Aug 5, 2026, 8:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 8:41 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$PLUS
Neutral
high confidence
Mentioned
$PLUS
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PLUSNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider selling activity and the execution price range, but it does not introduce new operational, financial, regulatory, or deal information.

02

Market read

For traders, this is mainly a sentiment check on insider activity; the 10b5-1 framing reduces interpretive weight.

03

What to watch

Traders may over-weight insider sales; the key incremental detail here is only the sale size, timing, and price range, not any change in guidance or strategy.

Relevance 4/10Novelty 3/10Timing: filed Aug 5, covering sales executed Aug 3 to Aug 4

Background

The article is an SEC Form 4 insider transaction disclosure for EPLUS Inc (PLUS), reported by the CFO, with sales executed over Aug 3 to Aug 4 under a 10b5-1 plan.

Company-level read

Ticker impact

$PLUSNeutralHigh confidence
Context

EPLUS CFO Marion Elaine D sold about $690K of PLUS shares via a 10b5-1 plan across four trades at roughly $95.12 to $97.40.

Expected impact

Likely limited, with any impact confined to short-term sentiment rather than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan; it discloses sale activity and pricing but no new company-specific operating or financial information.

Market effects

Sector

Minimal, as this is company-specific insider selling with no sector-wide signal.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may not reflect bearish expectations and could be mechanically scheduled compensation liquidity.

Key entities

  • Equity issuer
    PLUS

    EPLUS Inc, the issuer of the shares sold by the CFO.

  • Insider
    Marion Elaine D

    Chief Financial Officer reporting the Form 4 insider sale.

Read at source← All news

Related articles

AUG 5
$PLUSMedAI 8/10

Why ePlus (PLUS) Shares Are Plunging Today

ePlus (NASDAQ: PLUS) shares fell about 5% after the company reported Q2 2026 results. Revenue rose 1.9% year over year to $649.1 million and adjusted EPS was $1.28, both above Wall Street estimates. Despite the beat, investors focused on declining adjusted operating and free cash flow margins and a forecast of about 2% full-year EPS growth. Shares later traded near $92.31.

financialcontent.com4 min
AUG 4
$PLUSMed

ePlus (NASDAQ:PLUS) Surprises With Q2 CY2026 Sales

ePlus (NASDAQ:PLUS) reported Q2 CY2026 revenue of $649.1 million, up 1.9% year on year, exceeding market expectations. Non-GAAP profit was $1.28 per share, 11.8% above analysts’ consensus. The company cited extended lead times and shipment delays tied to an ongoing memory chip shortage.

financialcontent.com4 min
AUG 4
$PLUSMed

EPLUS INC (PLUS): Results of Operations and Financial Condition

EPLUS INC (PLUS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 5 ef20079242_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ePlus Reports First Quarter Fiscal Year 2027 Financial Results Managed Services Delivers Strong Performance and Increases Recurring Revenue ~ Reiterates Fiscal 2027 Guidance ~ First Quarter of Fiscal Year 2027 ● Net sales

SEC EDGAR 8-K6 min
AUG 4
$PLUSMed

ePlus Reports First Quarter Fiscal Year 2027 Financial Results

ePlus (NASDAQ: PLUS) reported Q1 FY2027 results for the three months ended June 30, 2026. Net sales rose 1.0% to $649.1 million and services revenue rose 2.6% to $119.4 million, while gross profit fell 1.5% to $151.3 million. Net earnings from continuing ops declined 5.4% to $30.3 million and adjusted EBITDA fell 9.2% to $47.8 million. The company reiterated FY2027 mid-single-digit growth guidance and declared a $0.27 quarterly dividend.

prnewswire.com6 min
JUL 13
$PLUSMed

PageGroup & Oxford Nanopore: Markets live

PageGroup shares rose over 11% after it reported Q2 gross profit of £198m, down 0.2% year on year but ahead of analyst expectations, and said it sees signs of market normalisation. ME Group International gained about 11% after interim results showed flat £154m sales. Plus500 shares fell on weaker cash margin, and Oxford Nanopore dropped 12% after H1 sales missed expectations at £116.5m.

investorschronicle.co.uk6 min